Literature DB >> 6720683

Infectious complications in 127 patients with hairy cell leukemia.

H M Golomb, L J Hadad.   

Abstract

Information regarding infectious complications was obtained on 127 patients with hairy cell leukemia who were diagnosed between March 1974 and April 1982. Forty-seven patients (37%) had 111 documented infections (cultures positive), and 40 patients (31.5%) had 113 nondocumented infections (no culture results available, or cultures negative). The remaining 40 patients (31.5%) had no significant infections during the course of their disease. Patients without infection lived significantly longer than did patients who developed an infection (92% v 49% were alive at 4 years; P = .0012). Thirty-three of the 47 patients with documented infection have died; 29 of an infectious problem and four of a noninfectious problem. There was also a statistically significant difference in actuarial survivals between the documented-infection and nondocumented infection groups (P = .007). The two most common types of infection were bacteremia (30 episodes) and pneumonia (27 episodes). In the culture-documented group with bacteremia, E coli and P aeruginosa caused ten and eight infections, respectively, and three infections were due to S aureus. There were eight systemic infections of nonbacterial origin; in five, the organism cultured was M kansasii, and three were fungal infections. Blood counts at the time of diagnosis were not correlated with subsequent development of infection. Patients with hairy cell leukemia have a significant susceptibility to infections that can affect morbidity and mortality. Many of the infectious complications encountered are those common in patients whose immune system is compromised; however, the occurrence of disseminated atypical mycobacterial disease requires a heightened awareness.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6720683     DOI: 10.1002/ajh.2830160410

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  11 in total

Review 1.  Hairy cell leukemia: clinical features and therapeutic advances.

Authors:  B C Lembersky; H M Golomb
Journal:  Cancer Metastasis Rev       Date:  1987       Impact factor: 9.264

2.  Atypical mycobacterial infection in hairy cell leukemia treated with cladribine.

Authors:  Chandramohan Ramasamy; Biswajit Dubashi; J Sree Rekha; Debdatta Basu; Ankit Jain; Tarun Kumar Dutta
Journal:  Indian J Hematol Blood Transfus       Date:  2012-10-09       Impact factor: 0.900

3.  Mediastinal and Disseminated Mycobacterium kansasii Disease in GATA2 Deficiency.

Authors:  Jana P Lovell; Christa S Zerbe; Kenneth N Olivier; Reginald J Claypool; Cathleen Frein; Victoria L Anderson; Alexandra F Freeman; Steven M Holland
Journal:  Ann Am Thorac Soc       Date:  2016-12

4.  Central nervous system involvement in hairy cell leukemia.

Authors:  H Knecht; H Budmiger; P Groscurth; R A Streuli
Journal:  Klin Wochenschr       Date:  1985-05-02

5.  Hairy cell leukemia masquerading as infective endocarditis.

Authors:  Chandramohan Ramasamy; Biswajit Dubashi; J Sree Rekha; Debdatta Basu; Ankit Jain; Tarun Kumar Dutta
Journal:  Indian J Hematol Blood Transfus       Date:  2012-01-31       Impact factor: 0.900

6.  Histoplasmosis in hairy cell leukemia: case report and review of the literature.

Authors:  E Weeks; C M Jones; V Guinee; R Shallenberger; G A Sarosi; P A Bunnell
Journal:  Ann Hematol       Date:  1992-09       Impact factor: 3.673

Review 7.  Immunological and genetic abnormalities in chronic lymphocytic leukaemia. Impact of the purine analogues.

Authors:  G Juliusson
Journal:  Drugs       Date:  1994       Impact factor: 9.546

8.  Isolated Splenic Mycobacterial Disease: A Cause of Persistent Fever in a Hairy Cell Leukemia Patient.

Authors:  Vassilios Papadopoulos; Charalambos Kartsios; Anastassia Spyrou; Kostas Loukidis; Spyridon Miyakis; Stavroula Pervana; Charalambos Makridis; Anna Kioumi; Ioannis Korantzis
Journal:  Case Rep Gastroenterol       Date:  2010-09-11

9.  Phase 2 study of ibrutinib in classic and variant hairy cell leukemia.

Authors:  Kerry A Rogers; Leslie A Andritsos; Lai Wei; Eric M McLaughlin; Amy S Ruppert; Mirela Anghelina; James S Blachly; Timothy Call; Dai Chihara; Anees Dauki; Ling Guo; S Percy Ivy; Lacey R James; Daniel Jones; Robert J Kreitman; Gerard Lozanski; David M Lucas; Apollinaire Ngankeu; Mitch Phelps; Farhad Ravandi; Charles A Schiffer; William E Carson; Jeffrey A Jones; Michael R Grever
Journal:  Blood       Date:  2021-06-24       Impact factor: 25.476

10.  Retrospective Evaluation of Hairy Cell Leukemia Patients Treated with Three Different First-Line Treatment Modalities in the Last Two Decades: A Single-Center Experience.

Authors:  Şeniz Öngören; Ahmet Emre Eşkazan; Selin Berk; Tuğrul Elverdi; Ayşe Salihoğlu; Muhlis Cem Ar; Zafer Başlar; Yıldız Aydın; Nükhet Tüzüner; Teoman Soysal
Journal:  Turk J Haematol       Date:  2017-12-01       Impact factor: 1.831

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.